Glico市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、最終用戶、地區和競爭對手分類，2021-2031年

全球Glico市場預計將從 2025 年的 18.7 億美元成長到 2031 年的 39.3 億美元，複合年成長率為 13.18%。

該領域全面研究被稱為聚醣的複雜碳水化合物結構，包括其合成、作用以及與脂質和蛋白質的相互作用，這些相互作用對於各種生物功能至關重要。該行業的成長主要受全球慢性病盛行率上升的驅動。這導致對最先進的精準診斷和以聚醣為中心的創新治療方法的需求增加，並擴展了其在藥物研發中的應用。此外，分析工具的持續技術進步，包括先進的生物資訊學和高解析度質譜技術，顯著提高了聚醣分析的效率。

2024年12月，領先的醣質學學研究網路GlycoNet宣布了一項約450萬美元的戰略投資，該投資將分配給21個獨立的醣質學學研究舉措。然而，市場擴張的主要障礙在於Glico研究的高昂成本，以及聚醣分析技術的複雜性，這些技術通常需要高水準的專業技能。

市場促進因素

全球Glico市場正受到醣質學領域技術突破的強勁推動，這些突破使得對複雜聚醣結構進行高精度、高效率的分析成為可能。先進的生物資訊軟體和高解析度質譜技術的最新進展，提高了對位點特異性聚醣構型和聚醣異構體的鑑定精度，而這些先前難以確定。此類技術進步對於加速眾多醫學和生物學領域的研究與發展至關重要。例如，Kyron.bio於2025年5月宣布獲得600萬美元的資金籌措，用於將糖技術應用於先進藥物研發，並強調這筆資金將直接用於增強其醣質學能力。此類投資將加速新型分析方法和平台的開發，最終拓展聚醣的知識和實際應用。

同時，Glico在診斷和治療領域的應用不斷拓展，正成為市場成長的關鍵引擎。隨著聚醣在從癌症到自體免疫疾病等疾病進展路徑中的作用日益受到重視，基於聚醣的診斷設備和治療方法的需求也隨之成長。 GlycoNex公司在臨床試驗方面取得的進展便是一個例證。該公司於2026年4月14日宣布，日本藥品和醫療設備管理局（PMDA）已核准其用於治療嚴重消化器官系統腫瘤的聚醣特異性抗體藥物複合體（ADC）GNX1021啟動I期人體臨床試驗。此外，對Glico基礎研究的持續投入也為此成長提供了支持。 2026年2月，水穀糖科學基金會向16個聚醣科學研究計畫提供了約7,000萬日圓的津貼，旨在加深人們對聚醣及其臨床應用的理解。這些進展凸顯了業界利用聚醣改善醫療效果的趨勢。

市場挑戰

全球Glico產業發展面臨的主要障礙之一是高昂的研究成本和複雜的聚醣分析技術，後者需要高度專業的技能。聚醣的複雜特性需要先進的設備和熟練的人員，這導致企業和研究機構的研發成本不斷增加。這一高昂的經濟門檻阻礙了對醣質學的新投資，延緩了有前景的研究進展，並阻礙了小規模機構進入該領域。因此，新型聚醣治療方法和診斷工具的開發速度直接受到限制。

例如，根據美國細胞生物學會的報告，美國國立衛生研究院（NIH）於2025年2月對研究中心的設施和管理費用設定了15%的上限。這實際上加重了進行複雜生物醫學研究（例如Glico分析）的團隊的財務負擔。間接成本回收率的降低迫使各機構自行承擔更大比例的營運和基礎設施成本，進一步加劇了財務障礙。這些財務限制阻礙了研究舉措的拓展和科學研究成果向市場化產品的轉化，直接減緩了市場成長。

市場趨勢

精準醫療的關鍵趨勢之一是糖基生物標記的日益廣泛應用。這主要透過分析個體糖譜來實現疾病的精準識別、預後預測和療效追蹤。這些獨特的糖結構能夠提供關於疾病和健康狀況的詳細信息，從而促進高效個性化醫療解決方案的發展。這一趨勢對於個人化醫療的發展至關重要，因為它為早期檢測和個人化治療提供了新的方向。例如，在2025年12月發布的報告《GlycanAge融資870萬美元，將「膨脹的」糖基時鐘轉化為醫院診斷工具》中，Tech Funding News報道稱，GlycanAge已籌集870萬美元，用於推進其以糖基為中心的診斷解決方案的臨床應用並擴大其全球覆蓋範圍。此類資金籌措凸顯了糖基作為現代醫療保健中可靠生物標記的地位日益受到認可。

另一個重要趨勢是疫苗製劑中對Glico的重視，充分利用聚醣在宿主-病原體相互作用和免疫系統識別中的關鍵作用。科學家正利用對聚醣結構的深入了解，開發更有效、更廣譜的疫苗，特別是針對那些利用糖化作用逃避免疫系統的病原體。這項策略旨在透過誘導更強、更具針對性的免疫反應，克服傳統疫苗技術的限制。倫敦衛生與熱帶醫學院宣布，已於2024年2月獲得1,230萬英鎊的資金，用於建立「糖細胞工程生物學任務中心」。該中心將致力於加速開發和生產以聚醣為中心的先進診斷方法、治療方法和疫苗，展現了利用Glico改善公共衛生狀況的共同承諾。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Glico市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（酵素、儀器、試劑、試劑盒）
  • 依應用領域（藥物發現、疾病診斷、病毒學、細胞生物學、腫瘤學等）
  • 按最終用戶（研究機構、診斷中心、醫院、臨床檢查室、製藥和生物技術公司等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美Glico市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲Glico市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區Glico市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲Glico市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲Glico生物學市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球Glico市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• GE Healthcare Life Sciences
• Takara Bio Inc.
• New England Biolabs, Inc.
• Qiagen NV
• Abcam Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Glycobiology Market is projected to grow from USD 1.87 Billion in 2025 to USD 3.93 Billion by 2031 at a 13.18% CAGR. This field entails the comprehensive examination of complex carbohydrate structures known as glycans, covering their production, roles, and engagements with lipids and proteins essential to various biological functions. The growth of this industry is largely fueled by the rising worldwide prevalence of chronic illnesses, which creates a need for cutting-edge precision diagnostics and innovative glycan-centered treatments, alongside expanding uses in pharmaceutical research and drug development. Furthermore, ongoing technological improvements in analytical tools, including sophisticated bioinformatics and high-resolution mass spectrometry, greatly improve the effectiveness of analyzing glycans.

In December 2024, the leading glycomics research network GlycoNet reported a strategic investment of roughly USD 4.5 million distributed among 21 unique glycomics research initiatives. However, a significant obstacle to the market's expansion is the high expense associated with glycobiology studies, combined with the complicated nature of glycan analysis methods that frequently demand extensive technical proficiency.

Market Driver

The Global glycobiology market is being strongly propelled by technological breakthroughs in glycomics that facilitate the highly accurate and efficient examination of intricate glycan structures. New developments in sophisticated bioinformatics software and high-resolution mass spectrometry improve the identification of site-specific glycosylation arrangements and glycan isomers that were formerly difficult to determine. Such technological progress is essential for speeding up research and development in multiple medical and biological disciplines. As an example, Kyron.bio reported securing a USD 6.0 million investment in May 2025 to apply glycan engineering to sophisticated drug creation, emphasizing the direct financial backing aimed at boosting glycomics capabilities. These financial infusions encourage the creation of new analytical methods and platforms, consequently broadening the knowledge and practical use of glycans.

At the same time, the growing diagnostic and therapeutic uses of glycobiology act as crucial growth engines for the market. Acknowledging the part glycans play in disease pathways, ranging from cancer to autoimmune conditions, drives the need for diagnostic instruments and treatments based on glycans. This progress in clinical trials is demonstrated by GlycoNex, Inc., which noted that on April 14, 2026, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan authorized the start of a Phase 1 first-in-human clinical trial for GNX1021, a glycan-focused antibody-drug conjugate intended for severe gastrointestinal tumors. Additionally, continuous funding for basic glycobiology studies supports this expansion. In February 2026, the Mizutani Foundation for Glycoscience granted around 70 million yen to 16 different glycoscience research endeavors, aiding in the general comprehension and clinical application of glycans. Together, these advancements highlight the industry's movement toward utilizing glycans to enhance medical results.

Market Challenge

A major obstacle hindering the growth of the global glycobiology industry arises from the high expenses associated with its research and the natural complication of glycan analysis techniques, which require advanced technical knowledge. The complex characteristics of glycans require sophisticated equipment and highly trained staff, thereby increasing the development and operational costs for businesses and research facilities. This high economic hurdle discourages fresh investments in glycomics, postpones the advancement of promising studies, and prevents smaller organizations from entering the sector. As a result, the speed of creating new glycan-focused treatments and diagnostic tools is directly obstructed.

As an illustration, the American Society for Cell Biology reported that in February 2025, the National Institutes of Health implemented a 15% limit on Facilities and Administration expenses for research centers, essentially raising the economic strain on groups performing complicated biomedical research like glycobiology analyses. Because of this decrease in indirect cost recuperation, institutions are forced to cover a greater portion of their operational and infrastructure costs, thereby exacerbating the financial obstacles. These economic limitations hinder the expansion of research initiatives and the conversion of scientific findings into marketable items, resulting in a direct deceleration of market expansion.

Market Trends

A major trend in precision medicine is the growing use of glycan-based biomarkers, which concentrates on applying distinct glycan profiles for accurate disease identification, outcome prediction, and tracking of therapy effectiveness. These distinct carbohydrate formations provide a detailed perspective on disease and health conditions, facilitating the creation of healthcare solutions that are both highly effective and customized. This movement is essential for advancing personalized medicine, as it supplies new focal points for early detection and individualized treatments. As an illustration, Tech Funding News noted in a December 2025 report titled 'GlycanAge grabs $8.7M to turn glycan 'inflammaging' clocks into hospital diagnostics,' that GlycanAge acquired $8.7 million to propel its glycan-focused diagnostic solutions for clinical implementation and broaden worldwide access. Such financial backing emphasizes the growing acknowledgment of glycans as reliable biomarkers within contemporary medical practices.

An additional key trend involves the deliberate emphasis on glycobiology within vaccine formulation, taking advantage of the crucial function glycans serve in host-pathogen dynamics and immune system detection. Scientists are utilizing a profound comprehension of glycan configurations to engineer vaccines that are more potent and offer wider protection, especially against infectious agents that employ glycosylation to hide from the immune system. This strategy seeks to surpass the constraints of conventional vaccine technologies by producing stronger and highly targeted immunological reactions. As stated by the London School of Hygiene & Tropical Medicine, a funding of £12.3 million was granted in February 2024 to create a GlycoCell Engineering Biology Mission Hub. This center focuses on quickening the identification and manufacturing of sophisticated glycan-centered diagnostics, treatments, and vaccines, demonstrating a unified push to utilize glycobiology for better public health results.

Key Market Players

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• GE Healthcare Life Sciences
• Takara Bio Inc.
• New England Biolabs, Inc.
• Qiagen N.V.
• Abcam Limited

Report Scope

In this report, the Global Glycobiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glycobiology Market, By Product

• Enzymes
• Instruments
• Reagents
• Kits

Glycobiology Market, By Application

• Drug Discovery
• Disease Diagnostics
• Virology
• Cell Biology
• Oncology
• Others

Glycobiology Market, By End User

• Research Institutes
• Diagnostic Centers
• Hospitals
• Clinical Laboratories
• Pharmaceutical & Biotechnology Companies
• Others

Glycobiology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Glycobiology Market.

Available Customizations:

Global Glycobiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Glycobiology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Enzymes, Instruments, Reagents, Kits)
  • 5.2.2. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)
  • 5.2.3. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Glycobiology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Glycobiology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Glycobiology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Glycobiology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Glycobiology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Glycobiology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Glycobiology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Glycobiology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Glycobiology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Glycobiology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Glycobiology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Glycobiology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Glycobiology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Glycobiology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Glycobiology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Glycobiology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Glycobiology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Glycobiology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Glycobiology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Glycobiology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Glycobiology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Glycobiology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Glycobiology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Glycobiology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Glycobiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Agilent Technologies, Inc.
• 15.4. Danaher Corporation
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. GE Healthcare Life Sciences
• 15.7. Takara Bio Inc.
• 15.8. New England Biolabs, Inc.
• 15.9. Qiagen N.V.
• 15.10. Abcam Limited

16. Strategic Recommendations

17. About Us & Disclaimer